Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE: BMY) will report first-quarter 2026 results on April 30, 2026. Company executives will discuss results on a conference call beginning at 8:00 a.m. ET and a live audio webcast will be available at investor.bms.com.
Materials will be posted on the Investor Relations site before the call, and a replay will be available approximately three hours after the call concludes.
Contact emails: media@bms.com and investor.relations@bms.com.
Bristol Myers Squibb (NYSE: BMY) announced positive interim Phase 3 results from the SUCCESSOR-2 study of oral mezigdomide combined with carfilzomib and dexamethasone (MeziKd) in relapsed or refractory multiple myeloma. MeziKd showed a statistically significant, clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone.
Safety was consistent with the known profile; patients will continue to be followed for overall survival and long-term safety. Data will be presented at a future medical meeting and shared with health authorities.
Bristol Myers Squibb (NYSE:BMY) announced FDA approval of Sotyktu (deucravacitinib) for adults with active psoriatic arthritis on March 7, 2026. Approval was supported by pivotal POETYK PsA-1 and PsA-2 trials where Sotyktu 6 mg once daily achieved ACR20 rates of 54% vs placebo 34% (PsA-1) and 54% vs placebo 39% (PsA-2) at Week 16. Common adverse reactions include upper respiratory infections, increased CPK, herpes simplex, mouth ulcers, folliculitis, and acne. Warnings include infections, malignancy including lymphomas, rhabdomyolysis, laboratory abnormalities, and potential risks related to JAK inhibition.
Bristol Myers Squibb (NYSE: BMY) declared a quarterly cash dividend of $0.63 per share. The Board set the dividend payable on May 1, 2026 to shareholders of record as of April 2, 2026.
This action returns cash to shareholders and reflects a scheduled quarterly distribution policy.
SystImmune and Bristol Myers Squibb (NYSE: BMY) reported that izalontamab brengitecan (iza-bren) met both dual primary endpoints of progression-free survival (PFS) and overall survival (OS) in a pre-specified interim analysis of a Phase III study (BL-B01D1-307; NCT06382142) in previously treated unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in China.
This is the third Phase III trial where iza-bren reached primary endpoint(s) and the first bispecific ADC in Phase III to report dual positive PFS/OS results in TNBC; data will be presented at an upcoming medical meeting.
Bristol Myers Squibb (NYSE: BMY) will participate in the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026. The company will appear in a fireside chat beginning at 9:50 a.m. ET.
Investors and the public can listen via the company investor site at http://investor.bms.com, and an archived recording will be available after the session.
Bristol Myers Squibb (NYSE: BMY) reported positive top-line results from an ex‑US Phase 2 registrational study (NCT05664737) of Reblozyl (luspatercept) in adults with alpha (α)-thalassemia.
Both non‑transfusion‑dependent and transfusion‑dependent cohorts met primary and key secondary endpoints: an Hb increase in NTD and ≥50% RBC transfusion reduction in TD. Safety matched Reblozyl's known profile. Data will be presented at a medical congress and discussed with China's regulator.
Bristol Myers Squibb (NYSE: BMY) announced the FDA has accepted the New Drug Application for iberdomide in relapsed or refractory multiple myeloma with a PDUFA target action date of August 17, 2026. The submission is based on MRD negativity results from the Phase 3 EXCALIBER-RRMM study (Stage 2 ~664 patients) and received Breakthrough Therapy designation.
The review is part of FDA Project Orbis for concurrent international review; EXCALIBER remains ongoing and PFS data are still maturing.
Bristol Myers Squibb (NYSE: BMY) reported fourth quarter and full-year 2025 financial results and will host a conference call and live audio webcast at 8:00 a.m. ET on February 5, 2026. A replay will be available on the company’s investor site about three hours after the call.
Investor and media contact emails are provided for follow-up.
Bristol Myers Squibb (NYSE: BMY) announced a partnership with soccer Hall-of-Famer Kasey Keller, who for the first time is publicly sharing his non-Hodgkin lymphoma journey and one-time treatment with Breyanzi (lisocabtagene maraleucel) to raise awareness on World Cancer Day.
The release highlights Breyanzi’s five FDA-approved indications, a 3-year follow-up showing a 62% average reduction in risk versus standard care, and Important Safety Information including Boxed WARNINGS for CRS, neurologic toxicities, and secondary hematologic malignancies.